Author:
Norris J S,Bielawska A,Day T,El-Zawahri A,ElOjeimy S,Hannun Y,Holman D,Hyer M,Landon C,Lowe S,Dong J Y,McKillop J,Norris K,Obeid L,Rubinchik S,Tavassoli M,Tomlinson S,Voelkel-Johnson C,Liu X
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Molecular Biology,Molecular Medicine
Reference37 articles.
1. Rubinchik S, Wang D, Yu H, Fan F, Luo M, Norris JS et al. A complex adenovirus vector that delivers FASL-GFP with combined prostate-specific and tetracycline-regulated expression. Mol Ther 2001; 4: 416–426.
2. Norris JS, Holman DH, Hyer ML, Bielawska A, El-Zawahry A, Chalfant C et al. Death receptors in cancer therapy. In: El-Deiry WS (ed). Ceramide, Ceramidase and FasL Gene Therapy in Prostate Cancer. Humana Press Inc.: Totowa, NJ, 2004, pp 323–338.
3. Holman DH, Hyer ML, El-Zawahry AM, Keller GM, Norris JS . Cancer gene therapy. In: Curiel DT, Douglas J (eds). Pro-Apoptotic Strategy in Cancer Gene Therapy. Humana Press Inc: Totowa, NJ, 2003, pp 273–286.
4. Voelkel-Johnson C, King DL, Norris JS . Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. Cancer Gene Ther 2002; 9: 164–172.
5. Sudarshan S, Holman DH, Hyer ML, Voelkel-Johnson C, Dong JY, Norris JS . In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer. Cancer Gene Ther 2005; 12: 12–18.
Cited by
53 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献